NCT05932888View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2023

Primary Completion Date

August 5, 2023

Study Completion Date

August 30, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

QLM3003

1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）

DRUG

QLM3003 Placebo

1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)

Trial Locations (1)

Unknown

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05932888 - Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter